Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €112.54 EUR
Change Today -0.97 / -0.85%
Volume 5.0
BM8 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:42 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

biomarin pharmaceutical inc (BM8) Snapshot

Open
€115.76
Previous Close
€113.51
Day High
€115.76
Day Low
€110.41
52 Week High
07/20/15 - €140.53
52 Week Low
09/17/14 - €51.01
Market Cap
18.1B
Average Volume 10 Days
155.1
EPS TTM
--
Shares Outstanding
161.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOMARIN PHARMACEUTICAL INC (BM8)

biomarin pharmaceutical inc (BM8) Details

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including drisapersen, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; talazoparib, an orally available poly-ADP ribose polymerase inhibitor for cancer treatment; BMN 111, a peptide therapeutic for achondroplasia treatment; BMN 044, BMN 045, and BMN 053 for DMD treatment; and cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as BMN 270 and BMN 250. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. S.A. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono. The company was founded in 1996 and is headquartered in San Rafael, California.

1,681 Employees
Last Reported Date: 03/2/15
Founded in 1996

biomarin pharmaceutical inc (BM8) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $916.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $480.6K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $528.2K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $417.7K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $409.6K
Compensation as of Fiscal Year 2014.

biomarin pharmaceutical inc (BM8) Key Developments

Biomarin Pharmaceutical Inc. Launches kNOWyourDuchenne, Comprehensive Program for Patients with Duchenne Muscular Dystrophy to Understand the Genetic Mutation

BioMarin Pharmaceutical Inc. announced the introduction of kNOWyourDuchenne, a program to help families and physicians obtain and interpret genetic testing for patients with Duchenne muscular dystrophy. This novel program will identify specific genetic mutations leading to Duchenne, which may help guide clinicians and caregivers to potential treatments in development. Interpretation of the test will be performed by an independent lab director. Currently, genetic test results may not fully inform families or physicians of what potential treatments a child might be eligible for on the basis of that child's mutation. Duchenne muscular dystrophy is the most common fatal genetic disorder diagnosed in childhood, affecting approximately 1 in every 3,500 live male births. BioMarin will provide genetic interpretation and testing services through kNOWyourDuchenne to patients and families at no cost throughout the duration of the program. kNOWyourDuchenne is accessible to eligible Duchenne patients. There are no treatments available in the US to target the genetic basis of Duchenne muscular dystrophy. Potential new therapies that target the cause of the disease are being studied. Patients, families, and physicians need to know the specific genetic mutation and understand what potential targeted therapy might address the underlying genetic cause of the disease. BioMarin is developing new treatments to target the underlying genetic cause of Duchenne, which would require a genetic test to determine if a patient might benefit from a treatment.

BioMarin Sells PARP Inhibitor to Medivation for $570 Million

Medivation has bought itself a global license to BioMarin's talazoparibin in a deal worth $570 million. Talazoparibin is a highly-potent, orally-available PARP inhibitor currently in a Phase III study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer. Under the terms of the deal, Medivation will pay BioMarin $410 million upfront, up to an additional $160 million upon the achievement of regulatory, and sales-based milestones and mid-single digit royalties for the drug, and assumes responsibility for all development for all indication.

BioMarin Pharmaceutical Inc. Receives Rare Pediatric Disease Designation from FDA for Drisapersen for the Potential Treatment of Duchenne Muscular Dystrophy

BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for drisapersen, a potential treatment for patients with Duchenne Muscular Dystrophy (DMD) who are amenable to exon 51 skipping treatment. The FDA has previously granted drisapersen Orphan and Fast Track Status, Breakthrough Therapy Designation, as well as Priority Review status, which is designated to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BM8:GR €112.54 EUR -0.97

BM8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $64.38 USD +1.47
Incyte Corp $116.57 USD +0.50
Jazz Pharmaceuticals PLC $162.21 USD -2.04
Momenta Pharmaceuticals Inc $18.59 USD +0.20
Vertex Pharmaceuticals Inc $126.73 USD +0.20
View Industry Companies
 

Industry Analysis

BM8

Industry Average

Valuation BM8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.1x
Price/Book 8.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMARIN PHARMACEUTICAL INC, please visit www.bmrn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.